Mobile

A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Study of Enzastaurin with 5 FU/LV plus Bevacizumab as Maintenance Regimen Following First Line Therapy for Metastatic Colorectal Cancer

Update Il y a 4 ans
Reference: EUCTR2007-003844-31

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To compare Arm A versus Arm B in terms of PFS measured from the time of randomization after completing 6 cycles of first-line therapy for metastatic CRC: • Arm A: 5-FU/LV plus bevacizumab in combination with enzastaurin • Arm B: 5-FU/LV plus bevacizumab in combination with placebo.

Inclusion criteria

  • Locally-advanced or Metastatic Colorectal Cancer

Links